J. Tol

1.6k citations
22 papers · 1.2k · h-index 11

Impact in

  • Oncology top 5%
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis
  • Hepatology top 5%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

  • Oncology 14
    • Colorectal Cancer Treatments and Studies 9
    • Cancer Treatment and Pharmacology 6
    • HER2/EGFR in Cancer Research 3
  • Pulmonary and Respiratory Medicine 9
    • Gastric Cancer Management and Outcomes 5
    • Advanced Breast Cancer Therapies 3
Co-authors
Cornelis J.A. Punt (5 shared papers)Miriam Koopman (5 shared papers)Allert H. Vos (3 shared papers)Annemieke Cats (3 shared papers)Irıs D. Nagtegaal (2 shared papers)Linda Mol (4 shared papers)Ninja Antonini (4 shared papers)C. J. Rodenburg (3 shared papers)
Journals
Annals of Oncology (5 papers)ESMO Open (2 papers)British Journal of Cancer (1 paper)Investigational New Drugs (1 paper)Journal of Clinical Medicine (1 paper)
Partner nations
NetherlandsUnited StatesBelgium

In The Last Decade

J. Tol

22 papers receiving 1.2k citations

Peers

J. Tol
Comparison fields: 5 of 78
  • Oncology 878
  • Hepatology 148
  • Cancer Research 258
  • Pathology and Forensic Medicine 234
  • Radiology, Nuclear Medicine and Imaging 265
Replace Ru Jia with:
Ru Jia China
Eun Yoon Cho South Korea
Mauro Loi Italy
Jen‐Kou Lin Taiwan
Peirong Ding China
Louise C. Connell United States
Peng Du China
Silvia Mezi Italy
Thomas B. Karasic United States
Yong Yi China
J. Tol relative to Ru Jia China Ru Jia's profile →
Citations per field
00.5×2×3×3.6×
Ru Jia · 1×
Citations per year

Countries citing papers authored by J. Tol

Since Specialization
Citations

This map shows the geographic impact of J. Tol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Tol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Tol more than expected).

Fields of papers citing papers by J. Tol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Tol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Tol. The network helps show where J. Tol may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Tol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Tol Line = papers co-authored together J. Tol links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
Annals of Oncology ·Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana, Camilo Garcia, Patrick Emonts, Lieveke Ameye, Sigrid Stroobants, Manon Huizing, P. Aftimos, J. Tol, Wim J.G. Oyen, Daniëlle J. Vugts, Otto S. Hoekstra, Carolina P. Schröder, C. Willemien Menke‐van der Houven van Oordt, Thomas Guiot, Adrienne H. Brouwers, Ahmad Awada, Elisabeth G.E. de Vries, P. Flamen
2015265
2
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
British Journal of Cancer ·Nikki Knijn, Leonie J. Mekenkamp, Marjolein Klomp, M. Elisa Vink-Börger, J. Tol, Steven Teerenstra, Jos W. R. Meijer, Maria Tebar, Sietske A. Riemersma, J. Han van Krieken, Cornelis J.A. Punt, Irıs D. Nagtegaal
2011235
3
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
Annals of Oncology ·J. Tol, Miriam Koopman, Michael Craig Miller, Arjan G.J. Tibbe, Annemieke Cats, G.J. Creemers, Allert H. Vos, Irıs D. Nagtegaal, Leon W.M.M. Terstappen, Cornelis J.A. Punt
2009178
4
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Annals of Oncology ·J. Tol, Miriam Koopman, C. J. Rodenburg, Annemieke Cats, G.J. Creemers, Jolanda Schrama, Frans Erdkamp, Allert H. Vos, Linda Mol, Ninja Antonini, Cornelis J.A. Punt
2008167
5
Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
Journal of Clinical Oncology ·C.J.A. Punt, J. Tol, C. J. Rodenburg, A. Cats, G-J. Creemers, Jolanda Schrama, F. Erdkamp, Allert H. Vos, Linda Mol, Ninja Antonini
2008104
6
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
Investigational New Drugs ·J. Tol, Annemieke Cats, Linda Mol, Miriam Koopman, Monique M.E.M. Bos, J. J. M. van der Hoeven, Ninja Antonini, J.H.J.M. van Krieken, Cornelis J.A. Punt
200853
7
The α2-macroglobulin gene in AD
Neurology ·M.N. Koster, Bart Dermaut, Marc Cruts, Jeanine J. Houwing‐Duistermaat, Gerwin Roks, J. Tol, Alewijn Ott, Albert Hofman, Gabriela Munteanu, Monique M.B. Breteler, C M van Duijn, Christine Van Broeckhoven
200053
8
Association of esophageal candidiasis and squamous cell carcinoma
Medical Mycology Case Reports ·Corine Delsing, Chantal P. Bleeker‐Rovers, Frank L. van de Veerdonk, J. Tol, J.W.M. van der Meer, Bart Jan Kullberg, Mihai G. Netea
201244
9
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients
European Journal of Cancer ·Nikki Knijn, J. Tol, Miriam Koopman, M.J.B.P. Werter, Alex L.T. Imholz, F.A.A. Valster, Linda Mol, Andrew Vincent, Steven Teerenstra, Cornelis J.A. Punt
201039
10
Genetic and environmental factors in Alzheimer's disease.
PubMed ·J. Tol, Gerwin Roks, Arjen J. C. Slooter, Cornelia M. van Duijn
199929
11
Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
Journal of Nuclear Cardiology ·E J Reuvekamp, Ben F. Bulten, A A Nieuwenhuis, M R A Meekes, Anton F. J. de Haan, J. Tol, Angela H.E.M. Maas, Suzette Elias‐Smale, Lioe‐Fee de Geus‐Oei
201519
12
Hypotension during intensive care stay and mortality and morbidity: a systematic review and meta-analysis
Intensive Care Medicine ·Jaap Schuurmans, Benthe T. B. van Rossem, Santino R. Rellum, J. Tol, Vincent C Kurucz, Niels van Mourik, Ward H. van der Ven, Denise P. Veelo, Jimmy Schenk, Alexander P. J. Vlaar
20249
13
Treatment of liver metastases from colorectal cancer.
PubMed ·J. Tol, C.J.A. Punt
20069
14
Fatal microscopic pulmonary tumour embolisms in patients with breast cancer: necessary knowledge for future medical practice.
PubMed ·Myrella Vlenterie, Ingrid M.E. Desar, Carla M.L. van Herpen, J. Tol
20146
15
3000 ORAL Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis
European Journal of Cancer Supplements ·J. Tol, Miriam Koopman, C. J. Rodenburg, A. Cats, G.J. Creemers, C.A.M. de Swart, F. Erdkamp, L. Mol, Ninja Antonini, Cornelis J. A. Punt
20074
16
Targeted therapy in advanced colorectal cancer, an update
Targeted Oncology ·J. Tol, Cornelis J. A. Punt
20073
17
352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
Annals of Oncology ·Noor Wortelboer, Stephen B. H. Kent, Inge R. Konings, Annemiek van Ommen‐Nijhof, Vincent van der Noort, E. van den Pol, Cristina Guerrero Páez, M. van Bekkum, H.J. Droogendijk, Frans Erdkamp, Danny Houtsma, Hendrika M. Oosterkamp, Annemieke van der Padt‐Pruijsten, E.J. Siemerink, J. Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein
20241
18
Differences in the Incidence of Hypotension and Hypertension between Sexes during Non-Cardiac Surgery: A Systematic Review and Meta-Analysis
Journal of Clinical Medicine ·Elke M.E. Bos, J. Tol, Fabienne C. de Boer, Jimmy Schenk, Henning Hermanns, Susanne Eberl, Denise P. Veelo
20241
19
487MO Overall survival with first versus second-line use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer
Annals of Oncology ·Noor Wortelboer, Annemiek van Ommen‐Nijhof, Inge R. Konings, Vincent van der Noort, E. van den Pol, Cristina Guerrero Páez, S. Bakker, Sjoerd Hovenga, A. Imholz, Y.J.L. Kamm, L. van Leeuwen-Snoeks, S. Luykx, C. M. P. W. Mandigers, A-M.V. Riel, J. Tol, A. van de Wouw, Saskia M. Wilting, A. Elise van Leeuwen‐Stok, Agnes Jager, Gabe S. Sonke
20251
20
233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry
ESMO Open ·Sandra M. E. Geurts, Nan Ding, Marissa Meegdes, Frans Erdkamp, Joan B. Heijns, J. Tol, Birgit E. P. J. Vriens, W. Dercksen, Kirsten N. A. Aaldering, Manon J. Pepels, Linda van de Winkel, Natascha A. J. B. Peters, A. van de Wouw, N. Teeuwen, Maaike de Boer, Vivianne C. G. Tjan‐Heijnen
20231

About J. Tol

J. Tol is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine, Surgery and Pathology and Forensic Medicine, having authored 22 papers that have together received 1.2k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (6 papers), Gastric Cancer Management and Outcomes (5 papers), Hemodynamic Monitoring and Therapy (3 papers), HER2/EGFR in Cancer Research (3 papers), Advanced Breast Cancer Therapies (3 papers), Cardiac, Anesthesia and Surgical Outcomes (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Oncology (878 citations), Hepatology (148 citations), Cancer Research (258 citations), Pathology and Forensic Medicine (234 citations) and Radiology, Nuclear Medicine and Imaging (265 citations). J. Tol has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Cornelis J.A. Punt, Miriam Koopman, Allert H. Vos, Annemieke Cats, Irıs D. Nagtegaal, Linda Mol, Ninja Antonini, C. J. Rodenburg, Jolanda Schrama and Steven Teerenstra. Their work appears in journals such as Annals of Oncology, ESMO Open, British Journal of Cancer, Investigational New Drugs and Journal of Clinical Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ru JiaBreakdown of academic impact, for papers by Eun Yoon ChoBreakdown of academic impact, for papers by Mauro LoiBreakdown of academic impact, for papers by Jen‐Kou LinBreakdown of academic impact, for papers by Peirong DingBreakdown of academic impact, for papers by Louise C. ConnellBreakdown of academic impact, for papers by Peng DuBreakdown of academic impact, for papers by Silvia MeziBreakdown of academic impact, for papers by Thomas B. KarasicBreakdown of academic impact, for papers by Yong Yi